MEDIAN Technologies at ECR 2014
- MEDIAN Technologies will present results of a study: “Identification of measurable lesions: an opportunity for improving reliability of RECIST assessments”;
- MEDIAN Technologies co-authored an oral presentation done by the Saga University, Japan: “RECIST management at investigator sites: evaluation of a cloud-based quality control of imaging evaluations in clinical trials”;
- MEDIAN Technologies co-authored a poster publication done by the University Hospital of Nice, France: “Cloud-based quality control for volume-based response assessment in clinical trials: a pilot study”
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced it will present the results of three studies at the European Radiology Congress (ECR), to be held next March 6-10, in Vienna, Austria. The ECR is the premier radiology conference in Europe and is organized by the European Society of Radiology (ESR).
“Identification of measurable lesions: an opportunity for improving reliability of RECIST assessments”: Response Evaluation Criteria in Solid Tumor (RECIST) is the main imaging criteria in oncology. Several limitations have however been documented, one of them consisting in the identification and management of “Measurable” Lesions (ML). In its will to improve RECIST-based patient monitoring, MEDIAN investigated new methods to help the selection of the most evaluable pulmonary lesions through thoracic CT scans. The study demonstrated that the management of measurable / non measurable lesions may affect the quality of diagnosis, and that visually discriminating which are the most reliable lesions is difficult for readers. However, the study demonstrated that identifying and selecting measurable lesions in a reliable way is doable and can be dramatically improved using computer aided systems. The poster of the study is available on the ECR website: http://posterng.netkey.at/esr/viewing/index.php?module=viewing_poster&task=&pi=120255&searchkey=0d2b357c701090168609379d2388035d
“RECIST management at investigator sites: evaluation of a cloud-based quality control of imaging evaluations in clinical trials”: Imaging evaluations for clinical trials in oncology request as far as possible a standardized application of criteria used to assess response to treatment. The study dealt with the setup and evaluation of a cloud-based quality control of imaging evaluations done at investigator sites, with the objective to standardize the application of RECIST (Response Evaluation Criteria in Solid Tumors) criteria. For the purpose of the study, MEDIAN solutions were deployed at investigator sites in Japan, France and Scotland, and all images and evaluation data were stored in a Japan-based data center. The study demonstrated both the feasibility and the benefits of a cloud implementation in the context of international multi-center studies. The quality control provided a strict compliance to RECIST criteria for all evaluations and improved the inter-reader agreement regarding the choice of target lesions. The presentation is scheduled in the “Trends in reporting, image management and mobile computing” session, March 6 2014, 10:30 – 12:00.
“Cloud-based quality control for volume-based response assessment in clinical trials: a pilot study”: Tumor volume may address some of the RECIST (Response Evaluation Criteria in Solid Tumors) limitations that jeopardize the consistency of imaging assessments in oncology trials. The study evaluated some investigational volume-based criteria, in the frame of a cloud implementation of MEDIAN solutions, with the objective to standardize response evaluations among investigators. The study compared volume-based criteria to RECIST regarding inter-reader agreement and evaluated the impact of a cloud-based quality control for establishing a consensus on the choice of target lesions and new lesions. The study showed that, unlike RECIST, volume-based criteria improve response agreement among readers when a consensus on target lesions is performed. The study also demonstrated the positive impact of a consensus about new lesions on response evaluation agreement. The poster of the study is available on the ECR website: http://posterng.netkey.at/esr/viewing/index.php?module=viewing_poster&task=&pi=120526&searchkey=dc54053815ae49b8b41942a342fe1a73&scrollpos=0
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”